Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Carducci

Showing results (21-30 of 322) with videos related to

Pageof 33
Sort By:
Urology|January 30, 2004
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit studyJanet R Walczak, Michael A Carducci,
The Canadian Journal of Urology|July 16, 2005
Advanced prostate cancer: the futureAndrew J Armstrong, Michael A Carducci
Mayo Clinic Proceedings|February 13, 2007
Prostate cancer: a practical approach to current management of recurrent diseaseJanet R Walczak, Michael A Carducci
Current Opinion in Urology|May 9, 2006
New drugs in prostate cancerAndrew J Armstrong, Michael A Carducci
Current Opinion in Pharmacology|August 7, 2003
Differentiation therapyAlexander I Spira, Michael A Carducci
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2005
Making bad cells go good: the promise of epigenetic therapyEdward A Sausville, Michael A Carducci
Current Oncology Reports|April 26, 2005
Chemotherapy for advanced prostate cancer: results of new clinical trials and future studiesAndrew J Armstrong, Michael A Carducci
Cancer Journal (Sudbury, Mass.)|January 23, 2013
From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancerMichael T Schweizer, Michael A Carducci
Cancer Treatment Reviews|October 11, 2016
Early use of chemotherapy in metastatic prostate cancerMark C Markowski, Michael A Carducci
Asian Journal of Andrology|January 11, 2012
Use of androgen deprivation therapy in prostate cancer: indications and prevalenceRoisin M Connolly, Michael A Carducci, Emmanuel S Antonarakis
Pageof 33

Showing results (21-30 of 322) with videos related to

Sort By:
Pageof 33
Urology|January 30, 2004
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit studyJanet R Walczak, Michael A Carducci,
The Canadian Journal of Urology|July 16, 2005
Advanced prostate cancer: the futureAndrew J Armstrong, Michael A Carducci
Mayo Clinic Proceedings|February 13, 2007
Prostate cancer: a practical approach to current management of recurrent diseaseJanet R Walczak, Michael A Carducci
Current Opinion in Urology|May 9, 2006
New drugs in prostate cancerAndrew J Armstrong, Michael A Carducci
Current Opinion in Pharmacology|August 7, 2003
Differentiation therapyAlexander I Spira, Michael A Carducci
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2005
Making bad cells go good: the promise of epigenetic therapyEdward A Sausville, Michael A Carducci
Current Oncology Reports|April 26, 2005
Chemotherapy for advanced prostate cancer: results of new clinical trials and future studiesAndrew J Armstrong, Michael A Carducci
Cancer Journal (Sudbury, Mass.)|January 23, 2013
From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancerMichael T Schweizer, Michael A Carducci
Cancer Treatment Reviews|October 11, 2016
Early use of chemotherapy in metastatic prostate cancerMark C Markowski, Michael A Carducci
Asian Journal of Andrology|January 11, 2012
Use of androgen deprivation therapy in prostate cancer: indications and prevalenceRoisin M Connolly, Michael A Carducci, Emmanuel S Antonarakis
Pageof 33